Outcomes of Adjuvant Mitotane after Resection of Adrenocortical Carcinoma: A 13-Institution Study by the US Adrenocortical Carcinoma Group

Journal of the American College of Surgeons

Volumn 222, Issue 4, 2016, Pages 480-490

  Postlewait, Lauren M ^a   Ethun, Cecilia G ^a   Tran, Thuy B ^b   Prescott, Jason D ^e   Pawlik, Timothy M ^e   Wang, Tracy S ^f   Glenn, Jason ^f   Hatzaras, Ioannis ^h   Shenoy, Rivfka ^h   Phay, John E ⁱ   Keplinger, Kara ⁱ   Fields, Ryan C ^j   Jin, Linda X ^j   Weber, Sharon M ^g   Salem, Ahmed ^g   Sicklick, Jason K ^c   Gad, Shady ^c   Yopp, Adam C ^k   Mansour, John C ^k   Duh, Quan Yang ^d   Seiser, Natalie ^d   Solorzano, Carmen C ^l   Kiernan, Colleen M ^l   Votanopoulos, Konstantinos I ^m   Levine, Edward A ^m   Staley, Charles A ^a   Poultsides, George A ^b   Maithel, Shishir K ^a   more..

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f MEDICAL COLLEGE OF WISCONSIN   (United States)

^g UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^h NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ OHIO STATE UNIVERSITY   (United States)

^j WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k UNIVERSITY OF TEXAS AT DALLAS   (United States)

^l VANDERBILT UNIVERSITY   (United States)

^m WAKE FOREST SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

MITOTANE; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ADRENAL CORTEX CARCINOMA; ADULT; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONFERENCE PAPER; FEMALE; HORMONE RELEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; TREATMENT OUTCOME; ADJUVANT CHEMOTHERAPY; ADRENAL CORTEX NEOPLASMS; ADRENALECTOMY; ADRENOCORTICAL CARCINOMA; AGED; CLINICAL TRIAL; DISEASE FREE SURVIVAL; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; RETROSPECTIVE STUDY; UNITED STATES;

ADRENAL CORTEX NEOPLASMS; ADRENALECTOMY; ADRENOCORTICAL CARCINOMA; ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; MITOTANE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; UNITED STATES;

EID: 84962376501     PISSN: 10727515     EISSN: 18791190     Source Type: Journal    
DOI: 10.1016/j.jamcollsurg.2015.12.013     Document Type: Conference Paper

References (45)

1. E. Kebebew, E. Reiff, Q.Y. Duh, and et al. Extent of disease at presentation and outcome for adrenocortical carcinoma: have we made progress? World J Surg 30 2006 872 878
2. R.D. Schulick, and M.F. Brennan Long-term survival after complete resection and repeat resection in patients with adrenocortical carcinoma Ann Surg Oncol 6 1999 719 726
3. H.R. Haak, J. Hermans, C.J. van de Velde, and et al. Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients Br J Cancer 69 1994 947 951
4. K.Y. Bilimoria, W.T. Shen, D. Elaraj, and et al. Adrenocortical carcinoma in the United States: treatment utilization and prognostic factors Cancer 113 2008 3130 3136
5. A. Kutikov, K. Mallin, D. Canter, and et al. Effects of increased cross-sectional imaging on the diagnosis and prognosis of adrenocortical carcinoma: analysis of the National Cancer Database J Urology 186 2011 805 810
6. T. Else, A.R. Williams, A. Sabolch, and et al. Adjuvant therapies and patient and tumor characteristics associated with survival of adult patients with adrenocortical carcinoma J Clin Endocrinol Metab 99 2014 455 461
7. T.S. Khan, H. Imam, C. Juhlin, and et al. Streptozocin and o,p'DDD in the treatment of adrenocortical cancer patients: long-term survival in its adjuvant use Ann Oncol 11 2000 1281 1287
8. A.A. Nelson, and G. Woodard Severe adrenal cortical atrophy (cytotoxic) and hepatic damage produced in dogs by feeding 2,2-bis(parachlorophenyl)-1,1-dichloroethane (DDD or TDE) Arch Pathol 48 1949 387 394
9. D.M. Bergenstal, R. Hertz, M.B. Lipsett, and R.H. Moy Chemotherapy of adrenocortical cancer with O,P'ddd Ann Intern Med 53 1960 672 682
10. R.A. Decker, P. Elson, T.F. Hogan, and et al. Eastern Cooperative Oncology Group study 1879: mitotane and adriamycin in patients with advanced adrenocortical carcinoma Surgery 110 1991 1006 1013
11. M. Terzolo, A. Angeli, M. Fassnacht, and et al. Adjuvant mitotane treatment for adrenocortical carcinoma N Engl J Med 356 2007 2372 2380
12. E.G. Grubbs, G.G. Callender, Y. Xing, and et al. Recurrence of adrenal cortical carcinoma following resection: surgery alone can achieve results equal to surgery plus mitotane Ann Surg Oncol 17 2010 263 270
13. P. Icard, P. Goudet, C. Charpenay, and et al. Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group World J Surg 25 2001 891 897
14. NCCN clinical practice guidelines in oncology neuroendocrine tumors. Version 1.2015. National Comprehensive Cancer Network website. Available at: http://www.nccn.org/professionals/physician-gls/f-guidelines.asp - site. Accessed September 11, 2015.
15. S.K. Williamson, D. Lew, G.J. Miller, and et al. Phase II evaluation of cisplatin and etoposide followed by mitotane at disease progression in patients with locally advanced or metastatic adrenocortical carcinoma: a Southwest Oncology Group Study Cancer 88 2000 1159 1165
16. E. Baudin, G. Pellegriti, M. Bonnay, and et al. Impact of monitoring plasma 1,1-dichlorodiphenildichloroethane (o,p'DDD) levels on the treatment of patients with adrenocortical carcinoma Cancer 92 2001 1385 1392
17. J. Abraham, S. Bakke, A. Rutt, and et al. A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist Cancer 94 2002 2333 2343
18. F. Daffara, S. De Francia, G. Reimondo, and et al. Prospective evaluation of mitotane toxicity in adrenocortical cancer patients treated adjuvantly Endocr Relat Cancer 15 2008 1043 1053
19. M. Kroiss, M. Quinkler, W.K. Lutz, and et al. Drug interactions with mitotane by induction of CYP3A4 metabolism in the clinical management of adrenocortical carcinoma Clin Endocrinol 75 2011 585 591
20. S.B. Edge, and C.C. Compton The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM Ann Surg Oncol 17 2010 1471 1474
21. D. Dindo, N. Demartines, and P.A. Clavien Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey Ann Surg 240 2004 205 213
22. A.M. Lerario, F.P. Worden, C.A. Ramm, and et al. The combination of insulin-like growth factor receptor 1 (IGF1R) antibody cixutumumab and mitotane as a first-line therapy for patients with recurrent/metastatic adrenocortical carcinoma: a multi-institutional NCI-sponsored trial Hormones Cancer 5 2014 232 239
23. A. Berruti, M. Terzolo, P. Sperone, and et al. Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial Endocr Relat Cancer 12 2005 657 666
24. M. Fassnacht, M. Terzolo, B. Allolio, and et al. Combination chemotherapy in advanced adrenocortical carcinoma N Engl J Med 366 2012 2189 2197
25. T. Gagliano, E. Gentilin, K. Benfini, and et al. Mitotane enhances doxorubicin cytotoxic activity by inhibiting P-gp in human adrenocortical carcinoma cells Endocrine 47 2014 943 951
26. R. Vassilopoulou-Sellin, V.F. Guinee, M.J. Klein, and et al. Impact of adjuvant mitotane on the clinical course of patients with adrenocortical cancer Cancer 71 1993 3119 3123
27. A.A. Kasperlik-Zaluska, B.M. Migdalska, S. Zgliczynski, and A.M. Makowska Adrenocortical carcinoma. A clinical study and treatment results of 52 patients Cancer 75 1995 2587 2591
28. G. Dickstein, C. Shechner, E. Arad, and et al. Is there a role for low doses of mitotane (o,p'-DDD) as adjuvant therapy in adrenocortical carcinoma? J Clin Endocrinol Metab 83 1998 3100 3103
29. B. Wangberg, A. Khorram-Manesh, S. Jansson, and et al. The long-term survival in adrenocortical carcinoma with active surgical management and use of monitored mitotane Endocr Relat Cancer 17 2010 265 272
30. T.E. Abdel-Aziz, P. Rajeev, G. Sadler, and et al. Risk of adrenocortical carcinoma in adrenal tumours greater than 8 cm World J Surg 39 2015 1268 1273
31. Z. Loncar, V. Djukic, V. Zivaljevic, and et al. Survival and prognostic factors for adrenocortical carcinoma: a single institution experience BMC Urol 15 2015 43
32. J.P. Luton, S. Cerdas, L. Billaud, and et al. Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy N Engl J Med 322 1990 1195 1201
33. L. Gratian, J. Pura, M. Dinan, and et al. Treatment patterns and outcomes for patients with adrenocortical carcinoma associated with hospital case volume in the United States Ann Surg Oncol 21 2014 3509 3514
34. M. Terzolo, A.E. Baudin, A. Ardito, and et al. Mitotane levels predict the outcome of patients with adrenocortical carcinoma treated adjuvantly following radical resection Eur J Endocrinol 169 2013 263 270
35. G. Abiven, J. Coste, L. Groussin, and et al. Clinical and biological features in the prognosis of adrenocortical cancer: poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients J Clin Endocrinol Metabolism 91 2006 2650 2655
36. A. Berruti, M. Fassnacht, E. Baudin, and et al. Adjuvant therapy in patients with adrenocortical carcinoma: a position of an international panel J Clin Oncol 28 2010 e401 e402 author reply e403
37. S. Sbiera, E. Leich, G. Liebisch, and et al. Mitotane inhibits Sterol-O-Acyl Transferase 1 triggering lipid-mediated endoplasmic reticulum stress and apoptosis in adrenocortical carcinoma cells Endocrinology 156 2015 3895 3990
38. M. Volante, M. Terzolo, M. Fassnacht, and et al. Ribonucleotide reductase large subunit (RRM1) gene expression may predict efficacy of adjuvant mitotane in adrenocortical cancer Clin Cancer Res 18 2012 3452 3461
39. C.L. Ronchi, S. Sbiera, M. Volante, and et al. CYP2W1 is highly expressed in adrenal glands and is positively associated with the response to mitotane in adrenocortical carcinoma PLoS One 9 2014 e105855
40. Berruti A. Efficacy of Adjuvant Mitotane Treatment (ADIUVO). Available at: https://clinicaltrials.gov/ct2/show/NCT00777244. Accessed December 28, 2015.
41. A. Redlich, N. Boxberger, D. Strugala, and et al. Systemic treatment of adrenocortical carcinoma in children: data from the German GPOH-MET 97 trial Klin Padiatr 224 2012 366 371
42. T.M. Kerkhofs, L.J. Derijks, M.H. Ettaieb, and et al. Short-term variation in plasma mitotane levels confirms the importance of trough level monitoring Eur J Endocrinol 171 2014 677 683
43. T.M. Kerkhofs, L.J. Derijks, H. Ettaieb, and et al. Development of a pharmacokinetic model of mitotane: toward personalized dosing in adrenocortical carcinoma Ther Drug Monit 37 2015 58 65
44. G. Lughezzani, M. Sun, P. Perrotte, and et al. The European Network for the Study of Adrenal Tumors staging system is prognostically superior to the international union against cancer-staging system: a North American validation Eur J Cancer 46 2010 713 719
45. F. Beuschlein, J. Weigel, W. Saeger, and et al. Major prognostic role of Ki67 in localized adrenocortical carcinoma after complete resection J Clin Endocrinol Metab 100 2015 841 849